ArticleCureus2025
Implications of Non-compliance in the Management of Chronic Polycystic Ovarian Syndrome.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Polycystic ovarian syndrome (PCOS) is a reproductive endocrine disorder characterized by an imbalanced luteinizing hormone (LH) to follicle-stimulating hormone (FSH) ratio, which can lead to a range of complications, including infertility, metabolic disturbances, and cardiovascular disease. Diagnosis is based on the Rotterdam criteria, which require the presence of at least two of three features: oligo- or anovulation, clinical and/or biochemical hyperandrogenism, and polycystic ovaries. This case study follows a patient, from ages 28 to 34, who presents with complications while managing her PCOS. Diagnostic tests first confirmed excess androgen production and oligo-amenorrhea, leading to the initiation of metformin hydrochloride (HCl) and Lo Loestrin Fe, a low-estrogen oral contraceptive. However, the patient failed to comply with her medication regimen. Four years later, the patient returned with ongoing irregular bleeding episodes and severe hirsutism. This case addresses the importance of understanding medication non-compliance in the management of chronic conditions such as PCOS, where factors such as financial hardship and lack of understanding about the condition can hinder treatment adherence. Improved patient education, proactive management of medication side effects, and assistance with healthcare costs are essential to improving adherence and long-term health outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.